Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Q-Griffithsin Intranasal Spray for COVID-19 Prophylaxis
NCT05122260Phase 1Completed
- Start
- Nov 2021
- Primary completion
- Jan 2022
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Q-Griffithsin with Placebo (2 arms). Primary endpoints: Safety of single exposure of Q-GRFT at 3 weeks, Product acceptability at 3 weeks and 1 more. Started Nov 2021; status: completed.
02
Drugs
q-griffithsin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05122260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05122260.